Orthofix Medical Inc. (OFIX) SEC Filings & Earnings Calls

Arbitration and settlement payments reduced cash; M6 product line discontinued.

“The decrease was due to arbitration award and settlement payments related to pending claims from three former executives terminated in 2023.” · word for word

Litigation Liability

“Litigation and investigation costs $2,185”

Regulatory Risk (Italy Payback)

“accrued $11.0 million related to the IMDP” · word for word

Debt Covenant Compliance

“As of June 30, 2026, the Company was in compliance with all required financial covenants.” · word for word

Reimbursement changes could still affect claim volumes or payer behavior.

“changes in claim volumes or payer behavior” · word for word

Potential dilution from increased shares under stock purchase plan.

“The SPP Amendment increases the number of shares of the Company's common stock available for issuance under the SPP by 1,250,000 shares.”

Medicare reimbursement cut of ~10% for non-invasive bone growth stimulators reduces revenue and profitability.

“average Medicare reimbursement for these codes to decline by approximately 10%” · word for word

Three-year financial targets withdrawn, indicating loss of visibility and potential structural headwinds.

“Company's three-year financial targets are no longer applicable.” · word for word

Former executive arbitration and litigation costs

“As of March 31, 2026, the Company had accrued $23.3 million related to the arbitration matters with the Former Executives.” · word for word

Securities class action lawsuits

“The Company and the individual defendants moved to dismiss the amended complaint on May 15, 2025.” · word for word

Italian Medical Device Payback liability

“As of March 31, 2026, the Company has accrued $10.8 million related to the IMDP, which it has classified within other long-term liabilities; however, the actual liability could be higher or lower than the amount accrued once all legal proceedings are resolved.” · word for word

M6 product line discontinuation impact

“Net sales from the M6 product lines decreased $4.2 million, or 94.2%, as a result of the discontinuation of the product lines in 2025.” · word for word

Activist Investor Pressure

“Engine Capital Management, L.P. ... 4,390,779 (1) 10.9%”

M6 Disc Revenue Dependency

“Net sales of $822.3 million, including sales from our M6 artificial cervical and lumbar discs, and pro forma net sales of $811.9 million, excluding net sales from our M6 discs” · word for word

Net Loss Persistence

“Reported net loss of $(92.2) million” · word for word

Preliminary results subject to adjustment; M6 product discontinuation impact.

“preliminary, unaudited net sales results... are based on current expectations and are subject to quarter-end closing adjustments”

Healthcare industry consolidation pricing pressure

“Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if a group purchasing organization or similar entity excludes us from being a supplier.” · word for word

Competitive pressure from new product developments

“The industry in which we operate is highly competitive. New product developments and improvements by our competitors could make our products or technologies non-competitive or obsolete.” · word for word

Third-party payor reimbursement risk

“Our ability to market products successfully depends, in part, upon the acceptance of the products not only by consumers, but also by independent third parties, including physicians, hospitals, and third-party payors.” · word for word

Clinical trial failure risk

“Clinical development is a lengthy and expensive process with an inherently uncertain outcome. Failure to successfully complete clinical trials and obtain regulatory approval for our product candidates within our anticipated timelines at reasonable costs to us, or at all, could have a material adverse effect on our business, operating results, and financial c” · word for word

Supply chain dependency on third-party manufacturers

“We depend on a limited number of third-party manufacturers and suppliers for manufacturing and processing activities, components, and raw materials. Failure of these third parties to perform as expected could result in substantial delays, increased costs or failures of our product development programs, or delayed or unsuccessful commercialization of our prod” · word for word

Discontinued M6 product lines impact revenue comparability.

“Impact from discontinuation of M6 product lines: $1.3M in Q4 2025 vs $5.8M in Q4 2024” · word for word

Discontinuation of M6 product lines may impact future revenue if not offset by new products.

“Impact from discontinuation of M6 product lines reduced net sales by $2.2M in Q3 2025.” · word for word

Litigation liability from former executives

“the Company has recorded an accounting accrual in the amount of $18.3 million, reflecting the Company’s current estimate of the value of severance and equity-based rights that would be owed to each of the Former Executives in a “without Cause” termination if they were each determined to be entitled to severance and equity-based rights, plus pre-judgment inte” · word for word

Securities class action lawsuits

“On August 21, 2024, a securities class action complaint captioned Bernal v. Orthofix Medical Inc., et al., Case No. 24-cv-00690, was filed in the United States District Court for the Eastern District of Texas” · word for word

Italian Medical Device Payback liability

“As of September 30, 2025, the Company has accrued $10.3 million related to the IMDP, which it has classified within other long-term liabilities; however, the actual liability could be higher or lower than the amount accrued once all legal proceedings are resolved” · word for word